169 related articles for article (PubMed ID: 9874327)
41. Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation.
Westeel FP; Mazouz H; Ezaitouni F; Hottelart C; Ivan C; Fardellone P; Brazier M; El Esper I; Petit J; Achard JM; Pruna A; Fournier A
Kidney Int; 2000 Oct; 58(4):1788-96. PubMed ID: 11012914
[TBL] [Abstract][Full Text] [Related]
42. Acute renal failure due to severe hypercalcemia and nephrocalcinosis treated with two doses of pamidronate in an infant with Williams-Beuren syndrome.
Baştuğ F; Nalçacıoğlu H; Baş VN; Tekatlı-Çelik B; Çetinkaya H; Yel S
Turk J Pediatr; 2018; 60(2):210-215. PubMed ID: 30325132
[TBL] [Abstract][Full Text] [Related]
43. Pamidronate and osteoporosis prevention in liver transplant recipients.
Pennisi P; Trombetti A; Giostra E; Mentha G; Rizzoli R; Fiore CE
Rheumatol Int; 2007 Jan; 27(3):251-6. PubMed ID: 16944154
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate.
Pecherstorfer M; Steinhauer EU; Rizzoli R; Wetterwald M; Bergström B
Support Care Cancer; 2003 Aug; 11(8):539-47. PubMed ID: 12783289
[TBL] [Abstract][Full Text] [Related]
45. Pamidronate used to attenuate post-renal transplant bone loss is not associated with renal dysfunction.
Lee S; Glicklich D; Coco M
Nephrol Dial Transplant; 2004 Nov; 19(11):2870-3. PubMed ID: 15466880
[TBL] [Abstract][Full Text] [Related]
46. Childhood cancer and hypercalcemia: report of a case treated with pamidronate.
Kutluk MT; Hazar V; Akyüz C; Varan A; Büyükpamukçu M
J Pediatr; 1997 May; 130(5):828-31. PubMed ID: 9152297
[TBL] [Abstract][Full Text] [Related]
47. Pamidronate treatment of hypercalcemia caused by vitamin D toxicity.
Chatterjee M; Speiser PW
J Pediatr Endocrinol Metab; 2007 Nov; 20(11):1241-8. PubMed ID: 18183797
[TBL] [Abstract][Full Text] [Related]
48. Uses and effectiveness of pamidronate disodium for treatment of dogs and cats with hypercalcemia.
Hostutler RA; Chew DJ; Jaeger JQ; Klein S; Henderson D; DiBartola SP
J Vet Intern Med; 2005; 19(1):29-33. PubMed ID: 15715044
[TBL] [Abstract][Full Text] [Related]
49. Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial.
Thürlimann B; Waldburger R; Senn HJ; Thiébaud D
Ann Oncol; 1992 Sep; 3(8):619-23. PubMed ID: 1450043
[TBL] [Abstract][Full Text] [Related]
50. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
[TBL] [Abstract][Full Text] [Related]
51. Effectiveness of pamidronate in severe neonatal hypercalcemia caused by subcutaneous fat necrosis: a case report.
Lombardi G; Cabano R; Bollani L; Del Forno C; Stronati M
Eur J Pediatr; 2009 May; 168(5):625-7. PubMed ID: 18726115
[TBL] [Abstract][Full Text] [Related]
52. Nephrotic syndrome induced by pamidronate.
ten Dam MA; Hilbrands LB; Wetzels JF
Med Oncol; 2011 Dec; 28(4):1196-200. PubMed ID: 20865462
[TBL] [Abstract][Full Text] [Related]
53. Severe Hypercalcemia in a Child With Acute Lymphoblastic Leukemia Relapse: Successful Management With Combination of Calcitonin and Bisphosphonate.
Tagiyev A; Demirbilek H; Tavil B; Buyukyilmaz G; Gumruk F; Cetin M
J Pediatr Hematol Oncol; 2016 Apr; 38(3):232-4. PubMed ID: 26907650
[TBL] [Abstract][Full Text] [Related]
54. Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post-menopausal osteoporosis.
Orr-Walker B; Wattie DJ; Evans MC; Reid IR
Clin Endocrinol (Oxf); 1997 Jan; 46(1):87-92. PubMed ID: 9059563
[TBL] [Abstract][Full Text] [Related]
55. Bisphosphonates for treatment of childhood hypercalcemia.
Lteif AN; Zimmerman D
Pediatrics; 1998 Oct; 102(4 Pt 1):990-3. PubMed ID: 9755274
[TBL] [Abstract][Full Text] [Related]
56. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
DiMeglio LA; Ford L; McClintock C; Peacock M
Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
[TBL] [Abstract][Full Text] [Related]
57. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
[TBL] [Abstract][Full Text] [Related]
58. Pamidronate treatment for hypercalcemia in an infant receiving parenteral nutrition.
Bryowsky JJ; Bugnitz MC; Hak EB
Pharmacotherapy; 2004 Jul; 24(7):939-44. PubMed ID: 15303458
[TBL] [Abstract][Full Text] [Related]
59. Immobilization hypercalcaemia responding to intravenous pamidronate sodium therapy.
McIntyre HD; Cameron DP; Urquhart SM; Davies WE
Postgrad Med J; 1989 Apr; 65(762):244-6. PubMed ID: 2594602
[TBL] [Abstract][Full Text] [Related]
60. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.
Jansson S; Tisell LE; Lindstedt G; Lundberg PA
Surgery; 1991 Sep; 110(3):480-6. PubMed ID: 1845370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
